Stock Track | Jazz Pharmaceuticals Soars 5.05% on Positive Earnings, Analyst Upgrades

Stock Track

02-27

Jazz Pharmaceuticals (JAZZ) stock surged 5.05% in Wednesday's intraday trading session, fueled by the company's impressive Q4 2024 earnings report and optimistic analyst commentary.

On Sunday, Jazz Pharmaceuticals announced its Q4 2024 financial results, which included record-breaking revenue of nearly $1.1 billion, a 15% year-over-year increase in net product sales for its blockbuster drug Epidiolex, and strong performances across its oncology portfolio. The company also provided upbeat revenue and earnings guidance for 2025, projecting continued growth.

Following the earnings release, multiple Wall Street analysts reaffirmed their bullish stance on JAZZ, with some raising their price targets on the stock. Baird analyst Joel Beatty raised his price target to $167, citing the company's strong execution and promising growth prospects. Stifel Nicolaus and Bank of America Securities also reiterated their "Buy" ratings on JAZZ.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1104802830"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1104802830\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1104802830?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 00:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104802830","market":"hk","top_or_hot":-1,"title":"Stock Track | Jazz Pharmaceuticals Soars 5.05% on Positive Earnings, Analyst Upgrades","media":"Stock Track","content":"<p>Jazz Pharmaceuticals (JAZZ) stock surged 5.05% in Wednesday's intraday trading session, fueled by the company's impressive Q4 2024 earnings report and optimistic analyst commentary.</p>\n\n<p>On Sunday, Jazz Pharmaceuticals announced its Q4 2024 financial results, which included record-breaking revenue of nearly $1.1 billion, a 15% year-over-year increase in net product sales for its blockbuster drug Epidiolex, and strong performances across its oncology portfolio. The company also provided upbeat revenue and earnings guidance for 2025, projecting continued growth.</p>\n\n<p>Following the earnings release, multiple Wall Street analysts reaffirmed their bullish stance on JAZZ, with some raising their price targets on the stock. Baird analyst Joel Beatty raised his price target to $167, citing the company's strong execution and promising growth prospects. Stifel Nicolaus and Bank of America Securities also reiterated their \"Buy\" ratings on JAZZ.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Jazz Pharmaceuticals Soars 5.05% on Positive Earnings, Analyst Upgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Jazz Pharmaceuticals Soars 5.05% on Positive Earnings, Analyst Upgrades\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-27 00:57</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Jazz Pharmaceuticals (JAZZ) stock surged 5.05% in Wednesday's intraday trading session, fueled by the company's impressive Q4 2024 earnings report and optimistic analyst commentary.</p>\n\n<p>On Sunday, Jazz Pharmaceuticals announced its Q4 2024 financial results, which included record-breaking revenue of nearly $1.1 billion, a 15% year-over-year increase in net product sales for its blockbuster drug Epidiolex, and strong performances across its oncology portfolio. The company also provided upbeat revenue and earnings guidance for 2025, projecting continued growth.</p>\n\n<p>Following the earnings release, multiple Wall Street analysts reaffirmed their bullish stance on JAZZ, with some raising their price targets on the stock. Baird analyst Joel Beatty raised his price target to $167, citing the company's strong execution and promising growth prospects. Stifel Nicolaus and Bank of America Securities also reiterated their \"Buy\" ratings on JAZZ.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1104802830","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104802830","pubTimestamp":1740589020,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Jazz Pharmaceuticals  stock surged 5.05% in Wednesday's intraday trading session, fueled by the company's impressive Q4 2024 earnings report and optimistic analyst commentary.On Sunday, Jazz Pharmaceuticals announced its Q4 2024 financial results, which included record-breaking revenue of nearly $1.1 billion, a 15% year-over-year increase in net product sales for its blockbuster drug Epidiolex, and strong performances across its oncology portfolio. The company also provided upbeat revenue and ea","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"股票赛道Jazz Pharmaceuticals因盈利积极和分析师上调评级而飙升5.05%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":1},"content_text":"Jazz Pharmaceuticals (JAZZ) stock surged 5.05% in Wednesday's intraday trading session, fueled by the company's impressive Q4 2024 earnings report and optimistic analyst commentary.\nOn Sunday, Jazz Pharmaceuticals announced its Q4 2024 financial results, which included record-breaking revenue of nearly $1.1 billion, a 15% year-over-year increase in net product sales for its blockbuster drug Epidiolex, and strong performances across its oncology portfolio. The company also provided upbeat revenue and earnings guidance for 2025, projecting continued growth.\nFollowing the earnings release, multiple Wall Street analysts reaffirmed their bullish stance on JAZZ, with some raising their price targets on the stock. Baird analyst Joel Beatty raised his price target to $167, citing the company's strong execution and promising growth prospects. Stifel Nicolaus and Bank of America Securities also reiterated their \"Buy\" ratings on JAZZ.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}